Yiqi Yangyin Huoxue Method in Treating IdiopathicPulmonary Fibrosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Table 1

Characteristics of included studies.

Studies (first author, year)	Location	Sample size (male/female)	Age (mean years)	Interventions	Duration (weeks)	Outcomes	Classification of disease (light/middle/severe)
Li et al. [28], 2013	Beijing, China	E:40/21; C:38/21	E:61.9 ± 11.2; C:60.7 ± 11.5	E: Feiwei Chongji; C: prednisone	8	(1)(2)(3)(9)	NM
Luo [29], 2010	Beijing, China	E:13/8; C:12/9	E:60.98 ± 9.22; C:65.12 ± 8.61	E: Feixiantongfang; C:Acetylcysteine	12	(1)(2)(3)(5)(6)(9)	E:5/23/2; C:4/22/4
Li et al. [30], 2015	Beijing, China	E:18/16; C:14/16	E:58.23 ± 8.35; C:59.98 ± 7.43	E: Yangyin Tongluo pill; C: acetylcysteine	12	(5)(9)	NM
Mi [31], 2015	Beijing, China	E:13/7; C:11/9	E:65 ± 9.453; C:68.1 ± 12.161	E: Feixiantongfang; C: acetylcysteine	12	(4)(5)(9)	NM
Li et al. [32], 2014	Beijing, China	E:14/9; C:13/9	E:59.97 ± 9.77; C:64.59 ± 10.37	E: Feibitongfang; C: prednisone	12	(1)(2)(3)(4)(5)(6)	E:0/18/3; C:0/17/5
Hu [33], 2007	Beijing, China	E:10/5; C:9/6	E:63.9 ± 9.4; C:65.6 ± 8.7	E: Baofeitang and Dahuangzhechong pill; C: prednisone	12	(1)(2)(3)(4)(5)(6)	E:3/12/0; C:1/13/1
Liu [34], 2017	Henan, China	E:29/11; C:28/12	E:66. 49 ± 1. 11; C:66. 03 ± 1. 16	E: Shenmai injection + Shenxiong injection + C; C: acetylcysteine + do xofylline injection	2	(1)(3)(9)	NM
Lin [35], 2007	Beijing, China	E:15/10; C:14/10	E:61.12 ± 9.22; C:65.04 ± 8.62	E: Feixiantongfang; C: prednisone	12	(1)(2)(3)(4)(5)(6)(7)(8)	E:3/18/4; C:2/9/3

(1), change of cough; (2), changes of chest pain; (3), changes in shortness of breath; (4), lung function vital capacity (FVC); (5), total lung capacity (TLC); (6), partial pressure of oxygen in blood (PaO₂); (7), adverse events; (8), SGRQ score; (9), 6-minute walk test distance (6MWT); NM: not mentioned; E: experimental group; C: control group.